Biogen Stock Price - BIIB

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last: $ 226.06 ◊ 0.00 (0.00%)
Company Name Stock Ticker Symbol Market Type
Biogen Inc BIIB NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.30 0.13% 226.06 228.33 225.16 225.41 225.76 19:49:52
Bid Price Ask Price Spread Spread % News
225.11 226.28 1.17 0.52% - 4
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
23,475 1,978,789 $ 226.49 $ 448,170,004 1,661,352 215.775 - 345.00
Last Trade Time Type Quantity Stock Price Currency
18:01:52 8 $ 226.28 USD

Biogen Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 41.70B 184.45M $ 4.43B 21.62 8.20 182.48M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Biogen News

Loading Messages....

Latest BIIB Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BIIB Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week225.16228.33220.51223.47502M0.90.40%
1 Month234.86242.712219.7229.25372M-8.8-3.75%
3 Months239247.88215.775231.32721M-12.94-5.41%
6 Months235.04247.88215.775230.85322M-8.98-3.82%
1 Year329.97345215.775258.93032M-103.91-31.49%
3 Years289.89388.67215.775284.87642M-63.83-22.02%
5 Years297.29480.18215.775298.99462M-71.23-23.96%

Biogen Description

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Tysabri and Tecfidera. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.